Plant breeding plays a vital role in ensuring global food security by increasing crop yields, improving nutritional quality ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The CRISPR biotech is now shelving the autoimmune program and slashing staff in order to focus its resources and its finances on the two lead cancer programs, whose data readouts have been delayed ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room ...

Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

Researchers developed a machine learning model, PAMmla, to predict properties of CRISPR-Cas9 enzymes, enhancing precision and ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day. Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some ...